{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T20:55:19Z","timestamp":1725483319012},"reference-count":36,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2010,2,18]],"date-time":"2010-02-18T00:00:00Z","timestamp":1266451200000},"content-version":"vor","delay-in-days":1685,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Addict"],"published-print":{"date-parts":[[2005,7,9]]},"abstract":"<jats:p>The objective of this study was to determine if combined psychotherapy and pharmacotherapy reduces reported depressive symptoms compared to an assessment only condition for active drug injectors over nine months. Using a randomized controlled trial at an outpatient academic research office, the researchers applied psychotherapy (eight sessions of cognitive behavioral therapy) plus pharmacotherapy (citalopram) to active injection drug users with a DSM\u2010IV diagnosis of major depression, dysthymia, substance\u2010induced mood disorder with symptoms persisting for at least three months, or major depression plus dysthymia, and a Modified Hamilton Rating Scale for Depression (MHRSD) score greater than 13. The MHRSD scale scores were then assessed at the completion of three, six, and nine months. Participants (<jats:italic>n<\/jats:italic> = 109) were 64% male and 82% Caucasian, with a mean baseline MHRSD score of 20.7. Depression subtypes included major depression only (63%), substance\u2010induced depression (17%), and double\u2010depression (17%). Study retention at nine months was 89% . At the completion of three months of acute treatment, 26% of combined treatment patients (<jats:italic>n<\/jats:italic> = 53), compared to 12% of control patients (<jats:italic>n<\/jats:italic> = 56), were in remission (<jats:italic>p<\/jats:italic> = .047). At both six and nine months, the between\u2010group differences in remission rates and mean MHRSD scores were insignificant, although the overall mean MHRSD score decreased from baseline (<jats:italic>p<\/jats:italic> &lt; .01). At all follow\u2010up assessments, depression remission was significantly associated with lower heroin use. Among active drug injectors diagnosed with depression, symptoms decline over time. Combined treatment is superior to an assessment\u2010only condition in depression remission rates at the end\u2010of\u2010treatment, but this difference does not persist.<\/jats:p>","DOI":"10.1080\/10550490591003684","type":"journal-article","created":{"date-parts":[[2005,10,6]],"date-time":"2005-10-06T19:52:59Z","timestamp":1128628379000},"page":"346-357","source":"Crossref","is-referenced-by-count":4,"title":["Persistence of Antidepressant Treatment Effects in a Pharmacotherapy Plus Psychotherapy Trial for Active Injection Drug Users"],"prefix":"10.1111","volume":"14","author":[{"given":"Michael D.","family":"Stein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley J.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debra S.","family":"Herman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer L.","family":"Anthony","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan E.","family":"Ramsey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan W.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,2,18]]},"reference":[{"key":"e_1_2_7_2_2","first-page":"225","article-title":"Psychiatric illness in male and female narcotic addicts","volume":"43","author":"Croughan JL","year":"1982","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1982.04290020021004"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0740-5472(99)00084-7"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1986.01800080025004"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005053-199302000-00001"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1983.04390010030004"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1983.04390010049006"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.9.1659"},{"key":"e_1_2_7_10_2","volume-title":"Relapse Prevention","author":"Marlatt GA","year":"1985"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1997.01830230033005"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1521-0391.1996.tb00307.x"},{"key":"e_1_2_7_13_2","first-page":"3","article-title":"Psychiatric research interviews for substance and mental disorders: phenomenologically based diagnosis in patients who abuse alcohol and drugs","volume":"34","author":"Hasin D","year":"1998","journal-title":"Psychopharmacol Bull"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1521-0391.1995.tb00441.x"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.1996.91685911.x"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.61.2.152"},{"key":"e_1_2_7_17_2","volume-title":"Structured Clinical Interview for DSM\u2010IV, Patient Version","author":"First M","year":"1995"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(85)90057-5"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.65.5.715"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1037\/h0035142"},{"key":"e_1_2_7_21_2","first-page":"309","article-title":"Clinical management\u2010imipramine = placebo administration manual: NIMH Treatment of Depression Collaborative Research Program","volume":"23","author":"Fawcett J","year":"1987","journal-title":"Psychopharmacol Bull"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0740-5472(92)90062-S"},{"key":"e_1_2_7_23_2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1192\/S0007125000297328","article-title":"The prophylactic efficacy of fluoxetine in unipolar depression","volume":"9","author":"Montgomery SA","year":"1988","journal-title":"Br J Psychiatry"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200005183422001"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0193-953X(05)70279-3"},{"key":"e_1_2_7_26_2","first-page":"13","article-title":"Overcoming treatment resistance in depression","volume":"59","author":"Nelson JC","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n0913"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1983.04390010059007"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.132.4.447"},{"key":"e_1_2_7_30_2","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1749-6632.1982.tb39485.x","article-title":"The use of antidepressants with methadone in depression methadone maintenance patients","volume":"12","author":"Woody GE","year":"1982","journal-title":"Ann N Y Acad Sci"},{"key":"e_1_2_7_31_2","first-page":"454","article-title":"Doxepin as adjunctive therapy for depressed methadone maintenance patients: a double blind study","volume":"43","author":"Titievsky J","year":"1982","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.55.2.153"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0376-8716(80)90187-8"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(00)00304-9"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/0740-5472(94)00076-4"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2002.00102.x"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0740-5472(00)00112-4"}],"container-title":["The American Journal on Addictions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1080%2F10550490591003684","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1080\/10550490591003684","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T02:49:00Z","timestamp":1698720540000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1080\/10550490591003684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,9]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,7,9]]}},"alternative-id":["10.1080\/10550490591003684"],"URL":"https:\/\/doi.org\/10.1080\/10550490591003684","archive":["Portico"],"relation":{},"ISSN":["1055-0496","1521-0391"],"issn-type":[{"value":"1055-0496","type":"print"},{"value":"1521-0391","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7,9]]}}}